Predictive Marker: HER2 in Esophageal Adenocarcinoma

  • Duminda Subasinghe
  • Nathan Acott
  • M. Priyanthi Kumarasinghe
Part of the Methods in Molecular Biology book series (MIMB, volume 1756)


HER2 positivity is based on the fundamental principle of amplification of the human epidermal growth factor receptor 2 (HER2) gene resulting in overexpression of the protein products . Arising from that a “HER2-positive cancer” is one that shows HER2 gene amplification and resultant protein expression as demonstrated by in situ hybridization and immunohistochemistry, respectively. Testing of the HER2 status is crucial to ensure selection of the correct patient who may benefit from target therapy for esophageal adenocarcinoma. Accurate testing is dependent on several pre-analytical and analytical factors including sample selection, laboratory techniques, and accurate interpretation of HER2 test results.

Key words

HER2 Immunohistochemistry In situ hybridization Esophageal adenocarcinoma Pathology 


  1. 1.
    Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T (2008) Analysis of EGFR, HER2 and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 8:363CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cobleigh MA, Vogel CL, Tripathy D, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648CrossRefPubMedGoogle Scholar
  3. 3.
    Al-Momani H, Barnes R, El-Hadi A, Shah R, Lewis WG, Edwards P (2012) Human epidermal growth factor receptor-2 in esophageal cancers: an observational study. World J Gastroenterol 18:6447–6451CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    al-Kasspooles M, Moore JH, Orringer MB, Beer DG (1993) Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54:213–219CrossRefPubMedGoogle Scholar
  5. 5.
    Jankowski J, Coghill G, Hopwood D, Wormsley KG (1992) Oncogenes and onco-suppressor gene in adenocarcinoma of the esophagus. Gut 33:1033–1038CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG (1995) The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 221:677–684CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Nagaraja V, Shaw N, Morey AL, Cox MR, Eslick GD (2016) HER2 expression in esophageal carcinoma and Barrett’s esophagus associated adenocarcinoma: an Australian study. Eur J Surg Oncol 42:140–148CrossRefPubMedGoogle Scholar
  8. 8.
    Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ (2005) HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 76:R1058–R1079CrossRefGoogle Scholar
  9. 9.
    Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y (1994) A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 13:3302–3311PubMedPubMedCentralGoogle Scholar
  10. 10.
    Gowryshankar A, Nagaraja V, Eslick GD (2014) HER2 status in Barrett’s esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol 5:25–35PubMedPubMedCentralGoogle Scholar
  11. 11.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 376:687–697CrossRefGoogle Scholar
  12. 12.
    Flejou JF, Paraf F, Muzeau F, Fékété F, Hénin D, Jothy S, Potet F (1994) Expression of c-erbB-2 oncogene product in Barrett’s adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 47:23–26CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K, Siewert JR, Harbeck N (1994) Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer 73:1785–1794CrossRefPubMedGoogle Scholar
  14. 14.
    Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS (2000) Her-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Human Pathol 31:35–39CrossRefGoogle Scholar
  15. 15.
    Rossi E, Grisanti S, Villanacci V, Della Casa D, Cengia P, Missale G, Minelli L, Buglione M, Cestari R, Bassotti G (2009) HER-2 overexpression/amplification in Barrett’s esophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med 13:3826–3833CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rossi E, Villanacci V, Bassotti G, Casa DD, Missale G, Minelli L, Cestari R (2006) Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol 15:125–130CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rauser S, Weis R, Braselmann H, Feith M, Stein HJ, Langer R, Hutzler P, Hausmann M, Lassmann S, Siewert JR, Höfler H, Werner M, Walch A (2007) Significance of HER2 low-level copy gain in Barrett’s cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 13:5115–5123CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Albrecht B, Hausmann M, Zitzelsberger H, Stein H, Siewert JR, Hopt U, Langer R, Höfler H, Werner M, Walch A (2004) Array based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett’s adenocarcinoma. J Pathol 203:780–788CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Villanacci V, Rossi E, Grisanti S, Bassotti G, Ferrari VD, Missale G, Minelli L, Cengia P, Marini G, Cestari R (2008) Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett’s esophagus: a translational approach. Minerva Gastroenterol Dietol 54:347–353PubMedPubMedCentralGoogle Scholar
  20. 20.
    Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A, Qiu X, Hicks DG, Peters JH, Zhou Z (2011) HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 24:899–907CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, Kono S, Kusano C, Itoi T, Fujimoto K, Moriyasu F, Grabsch HI (2016) Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer 19:553–560CrossRefPubMedGoogle Scholar
  22. 22.
    Gullo I, Grillo F, Molinaro L, Fassan M, De Silvestri A, Tinelli C, Rugge M, Fiocca R, Mastracci L (2015) Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open 3:E165–E170CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G (2017) HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol 143:835–841CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kumarasinghe MP, Morey A, Bilous M, Farshid G, Francis G, Lampe G, McCue G, Von Neumann-Cosel V, Fox SB (2017) HER2 testing in advanced gastric and gastro-esophageal cancer: analysis of an Australia-wide testing program. Pathology 49(6):575–581CrossRefPubMedGoogle Scholar
  25. 25.
    Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, Kulkarni S (2009) Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22:1457–1467CrossRefPubMedGoogle Scholar
  26. 26.
    Voduc D, Kenney C, TO N (2008) Tissue microarrays in clinical oncology. Semin Radiat Oncol 18:89–97CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yamashita-Kashima Y, Shu S, Yorozu K, Hashizume K, Moriya Y, Fujimoto-Ouchi K, Harada N (2014) Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization. Gastric Cancer 17:638–647CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Schoppmann SF, Jesch B, Zacherl J, Wrba F, Hejna M, Maresch J, Langer FB, Riegler MF, Pluschnig U, Birner P (2011) HER-2 status in primary esophageal cancer, lymph nodes and distant metastases. Br J Surg 98:1408–1413CrossRefPubMedGoogle Scholar
  29. 29.
    Wong DD, de Boer WB, Platten MA, Jo VY, Cibas ES, Kumarasinghe MP (2015) HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? Diagn Cytopathol 43:80–85CrossRefPubMedGoogle Scholar
  30. 30.
    Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG, Members of Ad-Hoc Committee on Immunohistochemistry Standardization (2007) Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 15:124–133CrossRefPubMedGoogle Scholar
  31. 31.
    Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG, Members of the Standardization Ad-Hoc Consensus Committee (2008) Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 16:513–520CrossRefPubMedGoogle Scholar
  32. 32.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134:907–922PubMedPubMedCentralGoogle Scholar
  33. 33.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology; College of American Pathologists (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013CrossRefPubMedGoogle Scholar
  34. 34.
    Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25:637–650CrossRefPubMedGoogle Scholar
  35. 35.
    Grogan TM, Grogan T, McElhinny A, Loftin I et al (2012) Interpretation Guide Ventana INFORM HER2 Dual ISH DNA Probe Cocktail Assay. Ventana Medical Systems Inc., Tucson, AZ, USA. Google Scholar
  36. 36.
    Heras A, King G, Oroudjev E, Vargas J, Flores EL, Romo MAG, Osorno AZ, Hidalgo CO, Key M (2011) Hydrophilic plus slides: a surface-modified microscope slide for improved tissue adhesion. Bio SB, Santa Barbara, CA, USA. Google Scholar
  37. 37.
    Rakha EA, Pinder SE, Bartlett JMS et al (2015) Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 68:93–99CrossRefGoogle Scholar
  38. 38.
    Xie R, Chung JY, Ylaya K, Williams RL, Guerrero N, Nakatsuka N, Badie C, Hewitt SM (2011) Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections. J Histochem Cytochem 59:356–365CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Li X, Chew SH, Chay WY, Lim-Tan SK, Goh LK (2013) Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer. BMC Res Notes 6:562CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    HER2/neu (4B5) Rabbit Monoclonal Primary Antibody, VENTANA [package insert] (2011) Ventana Medical Systems Inc., Tucson, AZ, USA.
  41. 41.
    Sapino A, Goia M, Recupero D, Marchiò C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 3:129CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    INFORM HER2 Dual ISH DNA PROBE Cocktail Assay, VENTANA [package insert] (2016). Ventana Medical Systems Inc., Tucson, AZ, USA.
  43. 43.
    Brügmann A, Lelkaitis G, Nielsen S, Jensen KG, Jensen V (2011) Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol 19:203–211CrossRefPubMedGoogle Scholar
  44. 44.
    HER2 IQFISH pharmDx, for Dako Omnis, DAKO [package insert]. Dako Denmark A/S., Glostrup, Denmark.
  45. 45.
    Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797–805CrossRefPubMedGoogle Scholar
  46. 46.
    Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH (2010) Her2 testing in gastric cancer: what is different in comparison to breast cancer? Pathologe 31:208–217CrossRefPubMedGoogle Scholar
  47. 47.
    Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A (2012) Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastresophageal junction cancer testing accuracy in Australia. Am J Surg Pathol 36:577–582CrossRefPubMedGoogle Scholar
  48. 48.
    Kumarasinghe MP, de Boer WB, Khor TS, Ooi EM, Jene N, Jayasinghe S, Fox SB (2014) HER2 status in gastric/gastro-esophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio? Pathology 46:184–187CrossRefGoogle Scholar
  49. 49.
    Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA (2017) HER2 testing and clinical decision making in gastresophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35:446–464CrossRefPubMedGoogle Scholar
  50. 50.
    Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Woo CG, Ho WJ, Park YS, Park SR, Ryu MH, Jung HY, Kang YK (2017) A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas. Pathology 49:38–43CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  • Duminda Subasinghe
    • 1
  • Nathan Acott
    • 2
  • M. Priyanthi Kumarasinghe
    • 3
    • 4
  1. 1.University Surgical UnitThe National Hospital of Sri LankaColomboSri Lanka
  2. 2.Immunohistochemistry, Anatomical PathologyPathWest, QE2 Medical CentrePerthAustralia
  3. 3.PathWest Laboratory MedicineQueen Elizabeth II Medical CentreNedlandsAustralia
  4. 4.School of Pathology and Laboratory MedicineUniversity of Western AustraliaCrawleyAustralia

Personalised recommendations